BS, Furman University, 2002
MS, Furman Univeristy, 2003
PhD, Michigan State University, 2009
Our group is interested in the synthesis of novel small molecule scaffolds, and peptide/small molecule conjugates for evaluation against eukaryotic pathogens. Early collaborations with the Morris group investigated modified ebselen and benzamidobenzoic acid scaffolds against Trypanosoma brucei, the causative agent of Human African Trypanosomiasis. More recently, we are investigating the therapeutic value of new diazetines arising from a novel cycloaddition between triazolinediones and acetylenic sulfides.
EPIC-Related Whitehead Group Publications:
1. Joice, A. C.; Harris, M. T.; Kahney, E. W.; Dodson, H. C.; Maselli, A. G.; Whitehead, D. C.; Morris, J. C. “Exploring the mode of action of ebselen in Trypanosoma brucei hexokinase inhibition” Int. J. Parasitol. Drug Drug Resist. 2013, 3, 154-160.
- Selected as “Editor’s Choice”.
2. Gordhan, H. M.; Patrick, S. L.; Swasy, M. I.; Hackler, A. L. †; Anayee, M. †; Golden, J. E.; Christensen, K. A.; Morris, J. C.; Whitehead, D. C. “Evaluation of substituted ebselen derivatives as potential tyrpanocidal agents” Bioorg. Med. Chem. Lett. 2017, 27, 537-541.
3. Gordhan, H. M.; Milanes, J. E.; Qiu, Y.; Golden, J. E.; Christensen, K. A.; Morris, J. C.; Whitehead, D. C. “A targeted delivery strategy for the development of potent trypanocides” Chem. Commun. 2017, 53, 8735-8738.